Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
A restless night’s sleep is an all-to-common side effect of living with multiple myeloma (MM). Especially if you are undergoing therapy. Melatonin can fix that.
Not only did I have trouble sleeping during my therapy but I continue to have trouble sleeping due to long-term side effects like my hemorrhagic cystitis (caused by cytoxan chemotherapy). Mel is an ideal multiple myeloma therapy.
My point is that living with MM, before, during or after active MM therapy can make sleep difficult. The first study linked below does not recommend melatonin for the MM survivor. The study gives a “on the other hand…”
Finally, my own experience over the past 25 or so years is that I take melatonin (MEL) a couple of times a week. 300 micrograms. I find MEL helps me fall asleep faster and stay asleep longer.
I’ve tried taking MEL for several nights in a row and I’ve found that the benefits seem to dissipate. If I take MEL only, say, once every few days, the effects work better for me.
After years of MEL supplementation, my conclusion is that melatonin helps me sleep and may even help keep me in complete remission from my multiple myeloma.
For more information about nutritional supplementation for cancer as well as cancer side effects, scroll down the page, post a question or comment and I will reply ASAP.
“Linked Articles- This article is part of a themed section on Recent Developments in Research of Mel and its Potential Therapeutic Applications. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.16/issuetoc…
Concluding remarks- As summarized inthis review, mel appears to have beneficial actions against haematological neoplasms, overall. The normal circadian pattern of secretion of melatonin from the pineal gland may determine its protective actions against haematological cancers.
The positive effects of mel are pro-apoptotic, pro-oxidative, anti-proliferative and immunomodulatory. Thus, the timing of exogenous melatonin administration may be critical in determining its efficacy as an oncostatic agent.
Importantly, mel also ameliorates the toxicity of many drugs used to treat haematological malignancies, including myelotoxicity and toxicity on non-haematological tissues.
Finally, clarification of the intracellular signalling network of mel’s anti-neoplastic actions will help to facilitate further basic research and clinical application of melatonin in the treatment of haematological neoplasms.
“Mel is a natural indoleamine produced by the pineal gland that has many functions, including regulation of the circadian rhythm. Many studies have reported the anticancer effect of melatonin against a myriad of cancer types. Cancer hallmarks include sustained proliferation, evading growth suppressors, metastasis, replicative immortality, angiogenesis, resisting cell death, altered cellular energetics, and immune evasion. Melatonin anticancer activity is mediated by interfering with various cancer hallmarks. This review summarizes the anticancer role of melatonin in each cancer hallmark. The studies discussed in this review should serve as a solid foundation for researchers and physicians to support basic and clinical studies on melatonin as a promising anticancer agent.”
“The epidemiological studies have indicated a possible oncostatic property of melatonin on different types of tumors. Besides, experimental studies have documented that melatonin could exert growth inhibition on some human tumor cells in vitro and in animal models.
The underlying mechanisms include antioxidant activity, modulation of melatonin receptors MT1 and MT2, stimulation of apoptosis, regulation of pro-survival signaling and tumor metabolism, inhibition on angiogenesis, metastasis, and induction of epigenetic alteration.
Melatonin could also be utilized as adjuvant of cancer therapies, through reinforcing the therapeutic effects and reducing the side effects of chemotherapies or radiation. Melatonin could be an excellent candidate for the prevention and treatment of several cancers, such as breast cancer, prostate cancer, gastric cancer and colorectal cancer…”
“There is highly credible evidence that melatonin mitigates cancer at the initiation, progression and metastasis phases. In many cases, the molecular mechanisms underpinning these inhibitory actions have been proposed. What is rather perplexing, however, is the large number of processes by which melatonin reportedly restrains cancer development and growth…”
The experimental findings, however, suggest that the advantages of using melatonin as a co-treatment with conventional cancer therapies would far exceed improvements in the wellbeing of the patients.
“MEL, the main hormone produced by the pineal gland, seems to exert antineoplastic activity both in vitro and in vivo. Moreover, several studies reported increased melatonin blood levels in cancer patients.
Plasma mel concentrations were determined in 46 patients with multiple myeloma and in 31 age matched healthy subjects. Venous blood was drawn between 7.30 and 9.30 a.m. and melatonin was assayed using a commercially available radioimmunoassay.
The data were analysed by Student’s t test and results reported as mean values +/- standard deviation. The patients with multiple myeloma showed significantly higher mean melatonin serum levels than healthy subjects .
This behaviour could actually represent a phenomenon secondary to an altered endocrine-metabolic balance caused by an increased demand of the developing tumor. On the other hand, the increased melatonin secretion might be considered as a compensatory mechanism due to its antimitotic action and therefore as an effort to secrete substances capable of regulating neoplastic growth.”
“”Our data support the hypothesis that one night of not getting enough sleep in older adults activates important biological pathways that promote biological aging,” said lead author Judith Carroll, PhD…”
The study group comprised 29 community-dwelling older adults. They were age 61-86 years and 48 percent were male. Participants underwent an experimental partial sleep deprivation protocol over four nights, including adaptation, an uninterrupted night of sleep, partial sleep deprivation (restricted 3 a.m. – 7 a.m.) and another uninterrupted night of sleep (recovery). Blood samples were obtained each morning to assess PBMC gene expression using Illumina HT-12 arrays.”
“Melatonin is known for its regulation of circadian rhythm. Recently, studies have shown that melatonin may have a positive effect on the skeleton. By increasing age, the melatonin levels decrease, which may lead to a further imbalanced bone remodeling…
In conclusion, 1-yr treatment with melatonin increased BMD at femoral neck in a dose-dependent manner, while high-dose melatonin increased vBMD in the spine…”